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ABSTRACT
Introduction: Most asthma patients have mild
disease, although the burden of mild asthma is
not well understood nor studied. Some evidence
suggests that many patients with mild asthma
experience suboptimal symptom control and
exacerbations. This study characterizes the
burden of illness and treatment patterns among
patients with a confirmed diagnosis of mild
asthma, defined as GINA Step 1 or Step 2, and
residing in China, France, Germany, Italy,
Japan, Spain, the United Kingdom, or the Uni-
ted States.
Methods: The Respiratory Disease-Specific Pro-
gramme prospective cross-sectional survey was
conducted with primary care and specialty
physicians in each of the eight countries.
Physician and patient surveys assessed demo-
graphic and clinical characteristics, frequency
and timing of asthma symptoms, exacerbations,
and rescue inhaler usage, the most recent
FEV1% predicted, and healthcare utilization.
GINA Step was determined by prescribed
treatment regimen. GINA Step 1 patients were
prescribed as-needed reliever medication and
Step 2 required treatment with a low-dose
inhaled corticosteroid, leukotriene receptor
antagonist, or theophylline. Treatment adher-
ence was assessed with the Morisky Medication
Adherence scale, disease control with the
Asthma Control Test, and work and activity
impairments with the Work Productivity and
Activity Impairment scale.
Results: The sample included 1115 GINA Step 1
and 2 patients, with 53% classified as Step 2.
Overall asthma control was suboptimal, with
reports of nocturnal symptoms (40.6%), symp-
tom worsening (10.5%), and rescue inhaler
usage in the last 4 weeks (33.6%). 25% of
patients were uncontrolled. The overall mean
number of exacerbations in the last 12 months
was 0.4, with a higher frequency of exacerba-
tions in Step 2 patients who also experienced
more exacerbations requiring treatment inten-
sification, an emergency department visit, or
hospitalization.
Conclusion: Mild asthma imposes a substantial
burden on patients, establishing the need for
comprehensive management plans and ongo-
ing support for treatment adherence.
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Asthma is a common, chronic respiratory dis-
ease estimated to affect 235–334 million people
worldwide [1]. Characteristic symptoms include
wheezing, shortness of breath, chest tightness
and/or cough, and expiratory airflow limitation,
with symptoms typically varying over time in
frequency and intensity [1, 2]. Treatment goals
emphasize symptom control, maintenance of
normal activity levels, and reduced risk of future
exacerbations, fixed airflow limitations, and
medication side effects. Importantly, treatment
options are guided by disease severity [2, 3].
According to the Global Initiative for
Asthma (GINA), severity can be determined
after several months of controller treatment
based on the type of therapy required for opti-
mal control of symptoms and exacerbations [2].
Mild asthma is asthma that is well controlled
with GINA Step 1 or Step 2 treatment with
as-needed reliever medication monotherapy or
low-intensity controller treatment, such as
low-dose inhaled corticosteroids (ICS), leuko-
triene receptor antagonists (LTRAs), or theo-
phylline [2].
Severe asthma is viewed as a major unmet
health need and is the focus of research and
international guidelines, consensus statements,
and recommendations to improve patient
management and outcomes [2, 4–6]. Results
from epidemiologic studies typically do not
distinguish between categories of asthma
severity, although it is widely accepted that
most patients have mild or very mild disease,
fewer have moderate disease and fewer still have
severe disease [7]. As many as 70% of all asth-
matics are thought to have mild persistent dis-
ease, [8] with one population-based cohort
study of more than 150,000 patients from Bri-
tish Columbia from 1996 to 2000 reporting
mild asthma in 67.1% of patients [9].
Of note, the burden of mild asthma is not
well understood nor studied, although some
evidence suggests control is suboptimal and
potentially due to inadequate treatment [10].
Patients with mild or moderate asthma experi-
ence exacerbations [11], and approximately
40% of almost 2000 patients with mild asthma
reported days with symptoms [12].
While optimal control and prevention of
future complications is important for all levels
of asthma severity [13], this survey characterizes
the global treatment patterns and the burden of
illness among individuals with mild asthma
who consulted physicians for routine care, with
patients residing in China, France, Italy, Japan,




Data were analyzed from the Respiratory
Disease-Specific Programme (DSP), a large,
multinational, prospective, cross-sectional sur-
vey that collects real-world data from primary
care and specialist physicians and their patients,
with a full description of methods reported
previously [14].
Surveys were undertaken in France, Ger-
many, Italy, Spain, the UK, and the USA (2013),
Japan (2012) and China (2010). Consenting
physicians completed patient record forms for
five consecutive patients diagnosed with
asthma, with these patients then invited to
complete a patient questionnaire at the end of
their visit with the physician. Consenting
patients responded to the survey confidentially.
Unique identification numbers assigned to
physicians and patients permitted linked anal-
ysis of the completed surveys. Physician- and
patient-completed forms were collected by local
fieldworkers, with identifying information
removed before submission of surveys for
analysis.
The research was conducted as a market
research survey in accordance with the
amended Declaration of Helsinki, adhering to
the ICC/ESOMAR International code on obser-
vational research, and performed in full accor-
dance with the rules of the US Health Insurance
Portability and Accountability Act 1996. IRB
approval was not necessary nor sought.
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Study Participants
Physician eligibility criteria included comple-
tion of medical training in the last 5–35 years,
treatment of patients with asthma, and
responsible for the care of at least three patients
with asthma per month. Inclusion criteria for
patients were 12 years or older with a physi-
cian-confirmed diagnosis of mild asthma, cate-
gorized as GINA Step 1 (intermittent based on
as-needed reliever medication) or GINA Step 2
(mild persistent asthma requiring treatment
with a low-dose ICS, LTRA, or theophylline) [2].
Patients who declined to respond to the survey
for whom a physician-completed form was
obtained were not excluded from analyses.
Variables and Assessments
The survey obtained physician- and patient-re-
ported demographic and clinical characteristics
including age, smoking history, employment
status, education, body mass index (BMI),
comorbidities, and results of the most recent
FEV1% predicted. GINA Step was determined by
patient’sprescribed treatment regimenat the time
of surveycompletionbasedonthemedical record.
Physicians reported the frequency and tim-
ing of asthma symptoms during the past 4-week
interval. This information was obtained during
their examination and interaction with patients
and based on patient report of symptoms.
Exacerbations were defined as physician-con-
firmed worsening of symptoms beyond normal
day-to-day variation, and treatment(s) pre-
scribed for exacerbations including hospitaliza-
tions, emergency department (ED) visits, and
use of rescue inhalers. Physicians reported the
number of asthma exacerbations during the
12 months preceding the survey, which was
intended to reduce the likelihood of variations
in exacerbation rates that could be attributed to
different allergy seasons in each country.
Physician- and patient-reported perceptions
of asthma control were recorded on a five-point
scale ranging from not at all controlled to
completely controlled. The validated Asthma
Control Test (ACT) [15] was also used to assess
patient-reported control of their disease. ACT
scores less than 20 indicated not well-controlled
or poorly-controlled asthma. Patient-reported
adherence to their asthma treatment was
assessed with the Morisky Medication Adher-
ence scale (MMAS-8) [16], which was modified
in accordance with information provided by Dr.
Morisky to adapt the scale for other chronic
diseases. The MMAS-8 has been validated for use
in several different countries and in patients
with various chronic health conditions [17]
including hypertension [18, 19], diabetes
[20, 21], and osteoporosis [22]. The 8-item
questionnaire assesses general adherence to
medications that are taken daily and provided a
measure of adherence among GINA Step 2
patients to their prescribed controller therapy
[16]. The MMAS-8 and ACT were not completed
by patients in Japan or China because validated
translations were not available.
Patients also reported frequency of rescue
inhaler use and exacerbations in the last
4 weeks, the number of visits related to their
asthma or asthma symptoms to any physician
in the preceding 12 months, and the number of
lost days at work. The Work Productivity and
Activity Impairment (WPAI) Specific Health
Problem questionnaire was completed by
patients, which yields four types of scores for
absenteeism, presenteeism, total work produc-
tivity loss, and total activity impairment in the
last 7 days. Higher scores indicated greater
impairment and less productivity [23].
Statistical Methods
Descriptive statistics were reported for all vari-
ables. The maximum sample available for each
variable was used. There was no replacement of
subjects if they did not respond to the survey.
Results were stratified by GINA Steps 1 and 2. All
analyses were performed with Stata 13.1 [24].
RESULTS
Eligible physicians completed 5811 physi-
cian-reported surveys. The eligible study sample
included 1115 patients for whom a physi-
cian-reported form was completed. Of these,
595 patients declined to participate in the
Adv Ther
survey and 520 patients completed surveys
(Fig. 1). A comparison of demographic and
clinical characteristics for patients who com-
pleted the survey and those who declined to
participate in this research revealed few differ-
ences with respect to sex, race, ethnicity, BMI,
smoking status, comorbid health conditions,
the occurrence of exacerbations, and medica-
tion adherence. Survey respondents were
slightly younger with a mean age of 36.8 years
compared to 40.4 years for nonrespondents. A
higher proportion of nonrespondents (39.2%)
were prescribed ICS compared to 29.6% of sur-
vey participants.
GINA Step 1 patients comprised 47% of the
total sample. The highest percentage of patients
onrescue-onlymedicationsandclassifiedasGINA
Step 1 was 64.3% in Germany, whereas the high-
est percentage of GINA Step 2 patients resided in
Japan at 78.9% and the UK at 76.9% (Table 1).
GINA Step 1 Patients 
(n=524) 
Total Physician-completed Forms for Respiratory Disease-
specific Survey 
(N=5811) 
Maximum Eligible Study Population including 
GINA Step 1 and Step 2 Patients 
(n=1115) 
GINA Step 2 Patients 
(n=591) 
Ineligible Patients at GINA Steps 3 to 5 
(n=4696) 
GINA Step 1 Patient- 
completed Forms 
(n=269) 
GINA Step 2 Patient- 
completed Forms 
(n=251) 
Fig. 1 Schematic of survey respondents
Table 1 Overall study population prescribed a GINA Step
1 or 2 regimen by country
Country Total, n (%) GINA Step, n (%)
1 2
France 115 (10.3) 43 (37.4) 72 (62.6)
Germany 196 (17.6) 126 (64.3) 70 (35.7)
Italy 101 (9.1) 43 (42.6) 58 (57.4)
Spain 175 (15.7) 97 (55.4) 78 (44.6)
United Kingdom 121 (10.9) 28 (23.1) 93 (76.9)
United States 253 (22.7) 139 (54.9) 114 (45.1)
Japan 71 (6.4) 15 (21.1) 56 (78.9)
China 83 (7.4) 33 (39.8) 50 (60.2)
Total 1115 (100.0) 524 (47.0) 591 (53.0)
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Table 2 Demographic and clinical characteristics of participants
Characteristic Total GINA Step, n (%)
n5 1115 1 2
n5 524 (47.0) n5 591 (53.0)
Age, years
Mean (SD) 38.4 (16.5) 35.6 (14.9) 40.8 (17.5)
95% CI 37.4, 39.3 34.4, 36.9 39.4, 42.2
Missing 2 0 2
Sex, n (%)
Female 589 (52.9) 271 (51.8) 318 (53.8)
Male 525 (47.1) 252 (48.2) 273 (46.2)
Missing 1 1 0
Race/ethnicity, n (%)
White/Caucasian 860 (77.5) 421 (80.7) 439 (74.7)
Asian, Indian subcontinent 23 (2.1) 9 (1.7) 14 (2.4)
Asian, other 14 (1.3) 8 (1.5) 6 (1.0)
Afro-Caribbean 8 (0.7) 4 (0.8) 4 (0.7)
Hispanic 26 (2.3) 16 (3.1) 10 (1.7)
Japanese 71 (6.4) 15 (2.9) 56 (9.5)
Maghreb 1 (0.1) 1 (0.2) 0 (0.0)
African American 17 (1.5) 11 (2.1) 6 (1.0)
Chinese 83 (7.5) 33 (6.3) 50 (8.5)
Other 7 (0.6) 4 (0.8) 3 (0.5)
Missing 5 2 3
BMI, kg/m2
Mean (SD) 24.8 (4.8) 24.6 (4.6) 24.9 (5.0)
95% CI 24.5, 25.1 24.2, 25.0 24.4, 25.3
Missing 60 22 38
Smoking status, n (%)
Current 113 (10.2) 65 (12.5) 48 (8.2)
Former 161 (14.5) 58 (11.2) 103 (17.5)
Never 833 (75.2) 396 (76.3) 437 (74.3)
Missing 8 5 3
Employment status, n (%)
Full-time 301 (50.8) 155 (52.5) 146 (49.2)
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Table 2 continued
Characteristic Total GINA Step, n (%)
n5 1115 1 2
n5 524 (47.0) n5 591 (53.0)
Part-time 34 (5.7) 11 (3.7) 23 (7.7)
Long-term disability 3 (0.5) 1 (0.3) 2 (0.7)
Student 129 (21.8) 77 (26.1) 52 (17.5)
Unemployed 33 (5.6) 16 (5.4) 17 (5.7)
Homemaker 30 (5.1) 17 (5.8) 13 (4.4)
Retired 59 (10.0) 18 (6.1) 41 (13.8)
Self-employed 3 (0.5) 0 (0.0) 3 (1.0)
Missing 523 229 294
Most recent FEV1 % predicted score, pre-bronchodilation
Mean (SD) 79.3 (18.2) 81.0 (16.7) 78.1 (19.1)
95% CI 77.7, 80.9 78.8, 83.3 75.9, 80.3
Missing 617 313 304
Most recent FEV1 % predicted score, post-bronchodilation
Mean (SD) 85.8 (15.3) 88.1 (13.0) 84.2 (16.6)
95% CI 84.3, 87.4 86.1, 90.1 81.9, 86.4
Missing 739 363 376
Comorbidities, n (%)
None 355 (31.9) 169 (32.3) 186 (31.5)
Allergic rhinitis 432 (38.8) 224 (42.7) 208 (35.3)
Anxiety 74 (6.6) 41 (7.8) 33 (5.6)
Arthritis 34 (3.1) 15 (2.9) 19 (3.2)
Depression 46 (4.1) 20 (3.8) 26 (4.4)
Dermatitis/eczema 10 (0.9) 1 (0.2) 9 (1.5)
Diabetes 38 (3.4) 12 (2.3) 26 (4.4)
Dyspepsia/stomach pain 28 (2.5) 12 (2.3) 16 (2.7)
GERD 60 (5.4) 17 (3.2) 43 (7.3)
Obesity 51 (4.6) 17 (3.2) 34 (5.8)
Sinusitis 15 (1.3) 8 (1.5) 7 (1.2)
Sleep apnoea 15 (1.3) 2 (0.4) 13 (2.2)
Missing 1 0 1
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Demographic and Clinical Characteristics
The mean patient age was 38.4 years. Slightly
more than 50% of the overall sample was
female, with approximately three-quarters cat-
egorised as White/Caucasian. A higher per-
centage of Step 1 patients were current smokers
at 12.5% versus 8.2% of GINA Step 2 patients
(Table 2).
FEV1 lung function evaluations indicated a
higher percent predicted for patients at GINA
Step 1. Approximately one-third of all patients
had no physician-confirmed comorbid health
conditions. Allergic rhinitis was the most fre-
quently diagnosed comorbidity among patients
(38.8%). Physicians identified asthma as the
primary health concern for approximately 75%
of patients (Table 2).
Asthma Treatment Regimens
and Adherence
Almost two-thirds of GINA Step 2 patients were
currently prescribed low-dose ICS (Table 3).
Xanthine monotherapy was used by only 5.6%
of Step 2 patients, with the majority of these
residing in Japan and China. Primary care
physicians were the sole provider of care for
47.3% of patients overall, with a slightly lower
proportion of GINA Step 2 patients treated only
by primary care clinicians. Treatment adher-
ence rates based on the MMAS-8 [16] for all
GINA Step 2 patients who were prescribed
regular maintenance medication were low for
35.6% of patients, medium for 38.1%, and high
for 26.3%.
Table 2 continued
Characteristic Total GINA Step, n (%)
n5 1115 1 2
n5 524 (47.0) n5 591 (53.0)
Physician reports asthma as main health concern for patient, n (%)
Yes 732 (76.8) 361 (76.5) 371 (77.1)
No 221 (23.2) 111 (23.5) 110 (22.9)
Missing 162 52 110
BMI body mass index, CI conﬁdence interval, FEV1 forced expiratory volume in one second, GERD gastroesophageal reﬂux
disease, SD standard deviation
Table 3 Current treatment regimens and treating
physicians
Treatment Total GINA Step, n (%)















0 (0.0) 377 (63.8)
LTRA alone 181
(16.2)
0 (0.0) 181 (30.6)
Xanthines alone 33 (3.0) 0 (0.0) 33 (5.6)










259 (50.2) 323 (54.9)
Missing 11 8 3
GINA global initiative for asthma, ICS inhaled corticos-
teroids, LTRA leukotriene receptor antagonist, SABA




There were minimal differences between patient
groups with respect to patients identifying
themselves as having poorly-controlled asthma.
Only 2.9% of patients overall, 2.9% of GINA
Step 1, and 2.8% of GINA Step 2 patients
self-classified as poorly controlled or uncon-
trolled. Physician ratings indicated that 3.5% of
Step 1 patients and 7.1% of Step 2 patients had
poorly-controlled or uncontrolled asthma
(Fig. 2i, ii). However, ACT scores for patients
revealed that 25.3% overall had scores less than
20, indicating that they were not well con-
trolled. Patients with lower ACT scores
accounted for a higher proportion of those
using reliever inhalers C3 times a week (Fig. 3).
There were some demographic and clinical
differences between patients who were well
controlled and those who were poorly con-
trolled or uncontrolled based on ACT scores
(Table 4). Poorly-controlled patients were more
likely to be female (58.1%) and current smokers
(12.4%) compared to 50.7% female and 8.5%
current smokers of those classified as well con-
trolled. Mean BMI was higher at 25.6 mg/kg2
(SD 5.3) for poorly-controlled asthmatics com-
pared to 24.4 mg/kg2 (SD 4.4) for those with
well-controlled disease. Patients with
poorly-controlled asthma were more likely to
have comorbid anxiety (8.5%) and depression
(10.1%) versus 4.5% with anxiety and 2.1%
with depression in patients who were well
controlled. A higher percentage of patients who
reported poor asthma control on the ACT were
treated with ICS alone (40.3%) while 54.5% of
well-controlled patients were prescribed
short-acting beta2-agonist (SABA) or short-act-
ing muscarinic antagonist (SAMA)
monotherapy.
ACT scores for all GINA Step 2 patients
revealed low adherence for 43.9% of
poorly-controlled patients compared to 32.1%
of those with ACT scores indicating good con-
trol. Medium adherence was evident for 37.9%
and 37.7% of poorly- and well-controlled GINA
Step 2 patients, respectively. High adherence
was reported by 18.2% of poorly-controlled
patients and 30.2% of those who were well
controlled.
Asthma Symptoms
The most frequently reported symptom was
shortness of breath during exertion for 30.9% of
patients overall, 28.4% of GINA Step 1, and
33.0% of GINA Step 2 patients. Overall, 40.6%
of patients reported nocturnal symptoms,
including symptoms occurring equally during
the day and night, primarily during the night,
and nighttime only. This was slightly higher
than the prevalence of physician-reported noc-
turnal symptoms at 36.5% for these same three
categories. Nocturnal symptoms during the day
and night, primarily during the night, and
nighttime only were indicated by 36.8% of Step
1 patients and 44.6% of those at Step 2 com-
pared with physician-reported rates of 34.3%
and 38.4%, respectively (Table 5).
Among patients prescribed rescue therapy,
8.5% of Step 1 and 10.9% of Step 2 patients
reported rescue inhaler use[2 times per week in
the 4 weeks preceding the survey. The frequency
of rescue inhaler use was similar between Step 1
and 2 patients with the exception of daily use,
which was reported twice as frequently by Step 2
patients (Table 5). Mean overall work impair-
ment due to asthma was 13.3%, while mean
activity impairment was 14.2% (Table 5).
Asthma Exacerbations
The majority of patients reported no significant
worsening of asthma symptoms in the last
4 weeks. However, 9.1% of Step 1 and 11.7% of
Step 2 patients indicated increased symptom
severity at least once or twice per week during the
4 weeks preceding the survey. The mean number
of exacerbations of any severity occurring in the
last 12 months for both Step 1 and Step 2 patients
was 0.4,with 19%of all patients experiencing one
or more exacerbations (Table 6).
The overall mean number of moder-
ate-to-severe exacerbations (requiring oral corti-
costeroids, antibiotics, treatment in the ED or
hospital admission) was 0.2. Overall, 12.5% of
patients had at least one moderate-to-severe
exacerbation, with a higher percentage of GINA
Step 2 patients experiencing exacerbations that
required temporary intensification of medical
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therapy with oral corticosteroids or antibiotics,
treatment in the ED, or hospitalization (Table 6).
DISCUSSION
Extensive research and clinical emphasis has
been placed on evaluation of the impact of
severe asthma on patients and healthcare sys-
tems, with new biologic treatments in devel-
opment specifically to address the unmet needs
of these patients [3, 25]. Patients with mild
asthma defined by GINA Steps 1 or 2 are
generally expected to have good or complete
control of symptoms and have a low risk for
exacerbations.
Our results indicate similarities between
physician and patient evaluations of asthma
control. Only 2.9% of patients overall consid-
ered themselves poorly controlled, while 3.5%
of Step 1 patients and 7.1% of Step 2 patients
were considered poorly controlled by their
physicians. However, a relatively large propor-
tion of patients were not well controlled
according to the ACT, a validated, objective
assessment of asthma control.
Fig. 2 i Patient-reported perceptions of asthma control. ii Physician-reported perceptions of asthma control. Excludes
patients from Japan where data was unavailable
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Other assessments of asthma symptoms and
exacerbations included overall patient-reported
occurrence of nocturnal symptoms (40.6%),
one or more significant worsening of symptoms
in the last 4 weeks (10.5%), and rescue inhaler
usage more than twice per week (9.7%). Further,
assessment of asthma control revealed that
approximately 25% of patients fell below the
threshold of 20 on the ACT, which is considered
an indication of poorly-controlled asthma.
Other research incorporating objective assess-
ments of asthma control and risk for exacerba-
tions reveals that a significant proportion of
patients with mild asthma are symptomatic,
experience exacerbations, and are not well
controlled [9, 11, 13].
For example, an observational, cross-sec-
tional, community-based study evaluated the
level of control in 950 adult patients with mild
asthma who were regularly treated by general
practitioners, with more than 80% prescribed
ICS [10]. Of these, only 13.7% were considered
totally controlled (ACT score of 25), 51.0% well
controlled (ACT score of 20–24), and 35.3%
were classified as not well controlled or poorly
controlled (ACT score B19) [10]. Patients with
poorly-controlled asthma were at significantly
greater risk for asthma-related unscheduled
visits to specialists, ED, and hospital admissions
[10].
Research suggests many patients perceive
their asthma as controlled and not serious
despite the occurrence of symptoms and exac-
erbations [26–28]. It has been suggested that
patients with mild disease may accept their
symptoms and have lower adherence to pre-
ventive therapy, possibly due to a lack of
understanding that therapy will control current
symptoms and reduce the risk of future disease
progression [13, 28].
Frequency of rescue inhaler usage, although
subject to variability, can be a useful proxy for
asthma control. Patients may use as-needed
relievers frequently but consider themselves
well controlled because rescue therapy pre-
vents their symptom escalation. However,
clinicians perceive the use of rescue therapy as
an indicator of poor asthma control. Our
results show less frequent use of rescue inhalers
was associated with better control character-
ized by higher ACT scores. This suggests that
accurate information about the frequency of
rescue inhaler usage can be a useful proxy to
assess control in the absence of reported
symptoms. One or more exacerbations in the
preceding 12 months was reported by 19% of
mild asthma patients overall experienced. This
suggests that approximately one in five
patients with mild asthma might benefit from
treatment intensification [2]. These results are
Fig. 3 Patient-reported level of asthma control by frequency of as-needed reliever use in the preceding 4 weeks. ACT
asthma control test
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Table 4 Demographic and clinical characteristics of participants by self-reported control of mild asthma
Characteristic Total ACT score, n (%)
n5 510 Poorly controlled: 5–19 Well controlled: 20–25
n5 129 (25.3) n5 381 (74.7)
Age, years
Mean (SD) 35.0 (15.6) 34.7 (15.1) 35.1 (15.7)
Sex, n (%)
Female 268 (52.5) 75 (58.1) 193 (50.7)
Male 242 (47.5) 54 (41.9) 188 (49.3)
BMI, kg/m2
Mean (SD) 24.7 (4.7) 25.6 (5.3) 24.4 (4.4)
Missing 28 6 22
Smoking status, n (%)
Current 48 (9.5) 16 (12.4) 32 (8.5)
Former 65 (12.8) 15 (11.6) 50 (13.3)
Never 393 (77.7) 98 (76.0) 295 (78.2)
Missing 4 5 3
Comorbidities, n (%)
None 178 (35.0) 44 (34.1) 134 (35.3)
Allergic rhinitis 194 (38.1) 51 (39.5) 143 (37.6)
Anxiety 28 (5.5) 11 (8.5) 17 (4.5)
Arthritis 16 (3.1) 4 (3.1) 12 (3.2)
Atopic dermatitis 11 (2.2) 2 (1.6) 9 (2.4)
Depression 21 (4.1) 13 (10.1) 8 (2.1)
Diabetes 12 (2.4) 3 (2.3) 9 (2.4)
GERD 30 (5.9) 5 (3.9) 25 (6.6)
Obesity 21 (4.1) 8 (6.2) 13 (3.4)
Missing 1 0 1
Physician responsible for treatment decisions, n (%)
Primary care only 240 (47.7) 60 (47.2) 180 (47.9)
Specialist involvement 263 (52.3) 67 (52.8) 196 (52.1)
Missing 7 2 5
Most recent FEV1% predicted score, pre-bronchodilation
Mean (SD) 81.0 (15.1) 78.3 (19.7) 81.8 (13.4)
Missing 265 72 193
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consistent with those reported from an earlier
Respiratory DSP survey [29] and highlight the
persistence of unmet needs for a significant
proportion of mild asthma patients.
Approximately half of patients were
employed full-time and about 20% were full--
time students. While the mean level of absen-
teeism was low, the mean impact of asthma on
productivity, overall work impairment, and
activity impairment ranged from 12% to 16%.
This provides an indication of the indirect eco-
nomic costs and restrictions on patient’s ability
to perform normal daily activities due to mild
asthma. GINA Step 1 patients reported less
work-related impairments compared to those
classified as GINA Step 2, suggesting higher
indirect costs and greater disease burden for
Step 2 patients.
Low adherence was evident for approxi-
mately a third of patients in this survey. Fur-
ther, a substantial proportion of patients were
considered by their physician to underestimate
the seriousness of their condition (data not
shown). This is consistent with findings from an
international survey of more than 10,000
asthma patients, which found that self-reported
classification of symptom control was not
aligned with guideline-based classification of
control [30]. These findings may reflect low
patient concern about their condition, placing
them at increased risk for future worsening of
their disease.
Table 4 continued
Characteristic Total ACT score, n (%)
n5 510 Poorly controlled: 5–19 Well controlled: 20–25
n5 129 (25.3) n5 381 (74.7)
Number of exacerbations in the last 12 months
0 412 (80.9) 96 (75.0) 316 (82.9)
1 55 (10.8) 16 (12.5) 39 (10.2)
2 30 (5.9) 10 (7.8) 20 (5.2)
C3 12 (2.4) 6 (4.7) 6 (1.6)
Missing 1 1 0
Current treatment, n (%)
SABA or SAMA 265 (51.2) 58 (45.0) 207 (54.5)
Low-dose ICS alone 167 (32.8) 52 (40.3) 115 (30.3)
LRA alone 76 (14.9) 19 (14.7) 57 (15.0)
Missing 1 0 1
MMAS-8a, n (%)
Low 81 (35.5) 29 (43.9) 52 (32.1)
Medium 86 (37.7) 25 (37.9) 61 (37.7)
High 61 (28.8) 12 (18.2) 49 (30.2)
Missing 282 63 219
ACT asthma control test, BMI body mass index, FEV1, GERD, gastroesophageal reﬂux disease, ICS inhaled corticosteroids,
LTRA leukotriene receptor antagonist, MMAS-8 morisky medication adherence scale, SABA short-acting beta2-agonist,
SAMA short-acting muscarinic antagonist, SD standard deviation
a Only GINA Step 2 patients
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Table 5 Symptoms, use of rescue inhaler, impact of asthma at work, and control of mild asthma
Characteristic Total GINA Step, n (%)
n5 1115 1 2
n5 524 (47.0) n5 591 (53.0)
Symptoms, n (%)
None 449 (40.3) 220 (42.0) 229 (38.7)
SOB at rest 104 (9.3) 50 (9.5) 54 (9.1)
SOB during exertion 344 (30.9) 149 (28.4) 195 (33.0)
SOB when exposed to trigger 259 (23.2) 133 (25.4) 126 (21.3)
Wheezing 286 (25.7) 64 (12.2) 161 (27.2)
Productive cough/sputum 141 (12.6) 138(26.3) 77 (13.0)
Dry cough 351 (31.5) 51 (9.7) 213 (36.0)
Regular clearing of throat 106 (9.5) 51 (9.7) 55 (9.3)
Tight feeling in chest 190 (17.0) 93 (17.7) 97 (16.4)
Bronchospasm/sudden tightening in chest 131 (11.7) 73 (13.9) 58 (9.8)
Other 9 (0.8) 4 (0.8) 5 (0.8)
Not indicated 1 (0.1) 1 (0.2) 0 (0.0)
Physician-reported time of day symptoms are most bothersome, n (%)
Daytime only 334 (31.5) 178 (36.4) 156 (27.2)
Primarily daytime, occasional nighttime 340 (32.0) 143 (29.2) 197 (34.4)
Equally day and nighttime 216 (20.3) 92 (18.8) 124 (21.6)
Primarily nighttime, occasional daytime 120 (11.3) 48 (9.8) 72 (12.6)
Nighttime only 52 (4.9) 28 (5.7) 24 (4.2)
Missing 53 35 18
Patient-reported time of day symptoms are most bothersome, n (%)
Daytime only 156 (26.4) 94 (31.4) 62 (21.2)
Primarily daytime, occasional nighttime 195 (33.0) 95 (31.8) 100 (34.2)
Equally day and nighttime 149 (25.2) 63 (21.1) 86 (29.5)
Primarily nighttime, occasional daytime 71 (12.0) 34 (11.4) 37 (12.7)
Nighttime only 20 (3.4) 13 (4.3) 7 (2.4)
Missing 524 225 299
Patient-reported use of rescue inhaler in last 4 weeks, n (%)
Not prescribed rescue inhaler 25 (4.9) 7 (2.7) 18 (7.3)
Not at all 190 (37.5) 103 (39.8) 87 (35.1)
Less than once/week 122 (24.1) 66 (25.5) 56 (22.6)
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It is conceivable that patients are unaware of
the distinction between poor and good asthma
control and may not understand how their
symptoms could be better controlled with
appropriate medical therapy. 64.4% of GINA
Step 2 patients were classified as of medium or
high adherence. This is slightly higher than
adherence rates reported in other studies, which
estimate that 50% of patients diagnosed with
mild, moderate, and severe asthma adhered to
Table 5 continued
Characteristic Total GINA Step, n (%)
n5 1115 1 2
n5 524 (47.0) n5 591 (53.0)
Once or twice/week 121 (23.9) 61 (23.6) 60 (24.2)
3–6 times/week 34 (6.7) 17 (6.6) 17 (6.9)
Daily 15 (3.0) 5 (1.9) 10 (4.0)
Missing 608 265 343
WPAI, percent work time missed
Mean (SD) 2.2 (10.4) 2.2 (12.9) 2.2 (7.5)
95% CI 0.9, 3.4 -0.1, 4.4 0.9, 3.4
Missing 850 396 454
WPAI, percent impairment while working
Mean (SD) 12.5 (16.9) 10.9 (16.0) 13.9 (17.6)
95% CI 10.4, 14.5 8.1, 13.7 10.9, 16.9
Missing 854 399 455
WPAI, percent overall work impairment
Mean (SD) 13.3 (18.1) 11.3 (16.7) 15.2 (19.2)
95% CI 11.1, 15.5 8.3, 14.2 12.0, 18.5
Missing 854 399 455
WPAI, percent activity impairment
Mean (SD) 15.5 (17.6) 14.2 (16.5) 16.9 (18.7)
95% CI 13.9, 17.1 12.1, 16.3 14.4, 19.3
Missing 654 289 365
ACT, n (%)
Not well controlled (ACT score, 5–19) 129 (25.3) 58 (21.8) 71 (29.1)
Well controlled (ACT score, 20–25) 381 (74.7) 208 (78.2) 173 (70.9)
Missing 605 258 347
Worsening of symptoms beyond normal day-to-day variations
ACT asthma control test, CI conﬁdence interval, GINA global initiative for asthma, SD standard deviation, SOB shortness
of breath, WPAI work productivity and impairment, speciﬁc health problem
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Table 6 Consultations for asthma and asthma exacerbations in the last 12 months
Consultations Total GINA Step, n (%)
n5 1115 1 2
n 5 524 (47.0) n5 591 (53.0)
Number of consultations in last 12 months for asthma
Mean (SD) 4.2 (4.1) 3.4 (3.0) 4.9 (4.8)
95% CI 4.0, 4.5 3.2, 3.7 4.5, 5.3
Missing 78 30 48
Number of PCP consultations in last 12 months for asthma
Mean (SD) 2.6 (4.4) 1.9 (2.4) 3.1 (5.6)
95% CI 2.3, 2.8 1.7, 2.1 2.7, 3.6
Missing 29 15 14
Number of pulmonologist or allergist consultations in last 12 months for asthma
Mean (SD) 0.6 (1.5) 0.5 (1.3) 0.7 (1.7)
95% CI 0.5, 0.7 0.4, 0.7 0.5, 0.9
Missing 54 238 307
Patient-reported worsening of symptoms in last 4 weeks, n (%)
Symptoms never get worse 51 (10.0) 24 (9.2) 27 (11.0)
Not at all 284 (55.9) 151 (57.6) 133 (54.1)
Less than once/week 120 (23.6) 63(24.0) 57 (23.2)
Once or twice/week 41 (8.1) 18 (6.9) 23 (9.3)
3–6 times/week 6 (1.2) 3 (1.1) 3 (1.2)
Daily 6 (1.2) 3 (1.1) 3 (1.2)
Missing 607 262 345
Number of exacerbationsa in last 12 months
Mean (SD) 0.4 (1.3) 0.4 (1.4) 0.4 (1.3)
95% CI 0.3, 0.4 0.2, 0.5 0.3, 0.5
Missing 2 1 1
Number of exacerbationsa in last 12 months, n (%)
0 901 (81.0) 439 (83.9) 462 (78.3)
1 124 (11.1) 47 (9.0) 77 (13.1)
2 59 (5.3) 19 (3.6) 40 (6.8)
C3 29 (2.6) 18 (3.4) 11 (1.9)
Missing 2 1 1
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their treatment regimen, [31] but is dependent
on the measurement of adherence. Improved
adherence may be achieved through imple-
mentation and ongoing review of asthma
action plans and ongoing patient education
regarding the importance of adherence and is
recommended by treatment guidelines for
patients with asthma of all degrees of severity
[2, 32].
Written personalized asthma action plans
are considered an essential component of a
self-management program for people with
asthma [32, 33]. An evidence-based review
found that individualized written plans were
associated with decreases in hospital admis-
sions, ED visits, unscheduled outpatient
appointments and improvements in markers of
asthma control and patient quality of life
[32, 34]. While we did not collect information
about asthma action plans in this survey,
patients with action plans were not excluded
from participation. Future surveys will include
questions to assess whether patients have
asthma action plans and any associations
between such plans, treatment modifications,
and the management of mild asthma.
Limitations
Patients included in the Respiratory DSP sample
were not a true random sample, since study
methods specified inclusion of five consecutive
patients who consulted their physician and met
study eligibility criteria. However, prospective
consecutive sampling does limit bias that might
be attributable to pre-selection of patients by
the physician.
Our findings are representative of patients
consulting a primary care physician or specialist
for routine care, which may limit
Table 6 continued
Consultations Total GINA Step, n (%)
n5 1115 1 2
n 5 524 (47.0) n5 591 (53.0)
Number of exacerbationsa treated in ED or hospital
Mean (SD) 0.1 (0.4) 0.1 (0.4) 0.1 (0.3)
95% CI 0.0, 0.1 0.0, 0.1 0.0, 0.1
Missing 39 10 29
Frequency of exacerbationsa treated with OCS, AB, ED, or hospital admission
Mean (SD) 0.2 (0.6) 0.1 (0.5) 0.2 (0.6)
95% CI 0.2, 0.2 0.1, 0.2 0.2, 0.3
Missing 116 42 74
Number of exacerbationsa treated with OCS, AB, ED, or hospital admission, n (%)
0 874 (87.5) 442 (91.7) 432 (83.6)
1 84 (8.4) 28 (5.8) 56 (10.8)
2 28 (2.8) 7 (1.5) 21 (4.1)
C3 13 (1.3) 5 (1.0) 8 (1.5)
Missing 116 42 74
AB antibiotics, CI conﬁdence interval, GINA global initiative for asthma, max maximum, min minimum, OCS oral
corticosteroid, ED emergency department, PCP primary care physician, SD standard deviation
a Physician-conﬁrmed worsening of symptoms beyond normal day-to-day variation
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generalizability to the general population of
mild asthmatics. There is the possibility of dif-
ferences between patients who agreed to com-
plete the survey and those who declined.
The diagnosis of asthma was confirmed by
physicians and dependent on their diagnostic
skills. However, this is a common and well-ac-
cepted method for the identification and
recruitment of samples in real-world research.
More than one-half of patients overall did not
have results for pre-bronchodilation FEV1% and
66.3% of all patients had missing results for
post-bronchodilation FEV1% data, with similar
proportions of missing data for Step 1 and 2
patients. This is consistent with general clinical
practice where it has been reported that
spirometry is infrequently used to assess asthma
control and treatment effectiveness in commu-
nity-dwelling patients with asthma [35–37].
Data on asthma symptoms were not collected
at a universally-recognized allergy season, which
was not possible given the number of countries
and variations between countries in the timing
of the allergy season. Therefore, the burden
related to asthma symptoms described here
could be an underestimation compared with the
asthma burden associated with allergy season.
The quality of the data depended on accurate
reporting by physicians and patients. Physicians
were permitted to refer to patient records,
which was intended to reduce errors in report-
ing treatment, clinical events and comorbidi-
ties. The majority of patient questions focused
on current or recent circumstances, which
helped reduce recall bias.
Physician inclusion in our study was poten-
tially influenced by their willingness to partici-
pate. We imposed minimal eligibility criteria
associated with the number of asthma patients
seen and active involvement in the manage-
ment of asthma patients. Thus, physicians were
likely to be representative of the general popu-
lation of clinicians caring for patients with
asthma.
CONCLUSION
While patients with mild asthma are expected
to have good or complete control of symptoms
and a low risk for exacerbations, our results
suggest a sizeable number are not well con-
trolled according to objective assessments.
Treatment adherence was suboptimal for
approximately three-quarters of Step 2 patients.
Interventions to promote adherence have the
potential to improve outcomes for some of
these patients, although it remains a possibility
that treatment intensification may offer addi-
tional clinical benefits.
ACKNOWLEDGEMENTS
Data collection was undertaken by Adelphi Real
World as part of a syndicated survey, entitled
the Respiratory Disease-Specific Programme,
sponsored by multiple pharmaceutical compa-
nies of which one was AstraZeneca. AstraZeneca
did not influence the original survey through
either contribution to the design of question-
naires or data collection. The study reported in
this manuscript was funded by AstraZeneca and
AstraZeneca funded all publication charges. All
authors contributed to the design, interpreta-
tion of the data, the writing of the report and
the decision to submit the paper for publica-
tion. All authors meet the International Com-
mittee of Medical Journal Editors criteria for
authorship for this manuscript, take responsi-
bility for the integrity of the work as a whole,
and have given final approval for the version to
be published. Carole Alison Chrvala, PhD of
Health Matters, Inc., funded by AstraZeneca, is
acknowledged for her assistance with writing
and editing this manuscript. The authors wish
to thank Adam Roughley for the analytical
support provided for this study. Preliminary
results of this study were previously presented
at a poster discussion session at the European
Respiratory Society Congress 2016
Compliance with Ethics Guidelines. The
research was conducted as a market research
survey in accordance with the amended Decla-
ration of Helsinki, adhering to the ICC/ESO-
MAR International code on observational
research and performed in full accordance with
the rules of the US Health Insurance Portability
Adv Ther
and Accountability Act 1996. IRB approval was
not necessary or sought.’’
Disclosures. Bo Ding is an employee of
AstraZeneca. Mark Small is an employee of
Adelphi Real World.
Data Availability. The datasets generated
during and/or analyzed during the current
study are not publicly available due their pro-
prietary nature but are available from the cor-
responding author on reasonable request.
Open Access. This article is distributed
under the terms of the Creative Commons
Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/
by-nc/4.0/), which permits any noncommer-
cial use, distribution, and reproduction in any
medium, provided you give appropriate credit
to the original author(s) and the source, provide
a link to the Creative Commons license, and
indicate if changes were made.
REFERENCES
1. The Global Asthma Report 2014. Auckland, New
Zealand: Global Asthma Network.
2. Global Initiative for Asthma. Global strategy for
asthma management and prevention. 2015. www.
ginasthma.org.
3. Reddel HK, Taylor DR, Bateman ED, et al. American
thoracic society/european respiratory society task
force on asthma control and exacerbations. An
official American thoracic society/European respi-
ratory society statement: asthma control and exac-
erbations: standardizing endpoints for clinical
asthma trials and clinical practice. Am J Respir Crit
Care Med. 2009;180(1):59–99.
4. Bel EH, Sousa A, Fleming L, et al. Unbiased
biomarkers for the prediction of respiratory disease
outcome (U-BIOPRED) consortium, consensus
generation. Diagnosis and definition of severe
refractory asthma: an international consensus
statement from the Innovative Medicine Initiative
(IMI). Thorax. 2011;66(10):910–7.
5. Chung KF, Wenzel SE, Brozek JL, et al. International
ERS/ATS guidelines on definition, evaluation and
treatment of severe asthma. Eur Respir J.
2014;43(2):343–73.
6. Jarjour NN, Erzurum SC, Bleecker ER, et al. NHLBI
Severe asthma research program (SARP). Severe
asthma: lessons learned from the national heart,
lung, and blood institute severe asthma research
program. Am J Respir Crit Care Med.
2012;185(4):356–62.
7. Chapman KR. Impact of ‘mild’ asthma on health
outcomes: findings of a systematic search of the
literature. Respir Med. 2005;99(11):1350–62.
8. O’Byrne PM. How much is too much? The treat-
ment of mild asthma. Eur Respir J.
2007;30(3):403–6.
9. Sadatsafavi M, Lynd L, Marra C, et al. Direct health
care costs associated with asthma in British
Columbia. Can Respir J. 2010;17(2):74–80.
10. Caminati M, Bettoncelli G, Magnoni MS, et al. The
level of control of mild asthma in general practice:
an observational community-based study.
J Asthma. 2014;51(1):91–6.
11. Dennis RJ, Solarte I, Rodrigo G. Asthma in adults.
BMJ Clin Evid. 2011 (pii: 1512).
12. O’Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al.
Low dose inhaled budesonide and formoterol in
mild persistent asthma: the OPTIMA randomized
trial. Am J Respir Crit Care Med. 2001;164(8 Pt
1):1392–7.
13. Shahidi N, Fitzgerald JM. Current recommenda-
tions for the treatment of mild asthma. J Asthma
Allergy. 2010;3:169–76.
14. Anderson P. Real-world physician and patient
behavior across countries: disease-Specific Pro-
grammes—a means to understand. Curr Med Res
Opin. 2008;24(11):3063–72.
15. Morisky DE, Ang A, Krousel-Wood M, Ward H.
Predictive validity of a medication adherence mea-
sure for hypertension control. J Clin Hypertens.
2008;10(5):348–54.
16. Plakas S, Mastrogiannis D, Mantzorou M, et al.
Validation of the 8-item Morisky Medication
Adherence Scale in chronically ill ambulatory
patients in rural Greece. Open J Nurs.
2016;6:158–69.
17. de Oliveira-Filho AD, Morisky DE, Neves SJ, Costa
FA, de Lyra DP Jr. The 8-item Morisky medication
adherence scale: validation of a Brazilian-Por-
tuguese version in hypertensive adults. Res Soc
Adm Pharm. 2014;10(3):554–61.
Adv Ther
18. Korb-Savoldelli V, Gillaizeau F, Pouchot J, et al.
Validation of a French version of the 8-item Morisky
medication adherence scale in hypertensive adults.
J Clin Hypertens (Greenwich). 2012;14(7):429–34.
19. Sakthong P, Chabunthom R, Charoenvisuthiwongs
R. Psychometric properties of the Thai version of
the 8-item Morisky Medication Adherence Scale in
patients with type 2 diabetes. Ann Pharmacother.
2009;43(5):950–7.
20. Wong MC, Wu CH, Wang HH, et al. Association
between the 8-item Morisky medication adherence
scale (MMAS-8) score and glycaemic control among
Chinese diabetes patients. J Clin Pharmacol.
2015;55(3):279–87.
21. Reynolds K, Viswanathan HN, O’Malley CD, et al.
Psychometric properties of the Osteoporosis-speci-
fic Morisky Medication Adherence Scale in post-
menopausal women with osteoporosis newly
treated with bisphosphonates. Ann Pharmacother.
2012;46(5):659–70.
22. Nathan RA, Sorkness CA, Kosinski M, et al. Devel-
opment of the asthma control test: A survey for
assessing asthma control. J Allergy Clin Immunol.
2004;113(1):59–65.
23. Reilly MC, Zbrozek AS, Dukes EM. The validity and
reproducibility of a work productivity and activity
impairment instrument. PharmacoEconomics.
1993;4(5):353–65.
24. StataCorp. Stata statistical software: release 13.
College Station: StataCorp LP; 2013.
25. Kupczyk M, Wenzel S. US and European severe
asthma cohorts: what can they teach us about sev-
ere asthma? J Intern Med. 2012;272(2):121–32.
26. Price D, Fletcher M, van der Molen T. Asthma
control and management in 8,000 European
patients: the REcognise Asthma and LInk to symp-
toms and experience (REALISE) survey. NPJ Prim
Care Respir Med. 2014;24:14009.
27. Price D, David-Wang A, Cho SH, et al. Time for a
new language for asthma control: results from
REALISE Asia. J Asthma Allergy. 2015;8:93–103.
28. Rabe KF, Adachi M, Lai CK, et al. Worldwide
severity and control of asthma in children and
adults: the global asthma insights and reality sur-
veys. J Allergy Clin Immunol. 2004;114(1):40–7.
29. Roberts J, Williams A. Quality of life and asthma
control with low-dose inhaled corticosteroids. Br J
Nurs. 2004;13(19):1124–9.
30. Nathan RA, Thompson PJ, Price D, et al. Taking aim
at asthma around the world: global results of the
asthma insight and management survey in the
Asia-Pacific Region, Latin America, Europe, Canada,
and the United States. J Allergy Clin Immunol
Pract. 2015;3(5):734–42.
31. Chiu KC, Boonsawat W, Cho SH, et al. Patient’s
beliefs and behaviors related to treatment adherence
in patients with asthma requiring maintenance
treatment in Asia. J Asthma. 2014;51(6):652–9.
32. Pinnock H. Supported self-management for asthma.
Breathe (Sheff). 2015;11(2):98–109.
33. Ring N, Malcolm C, Wyke S, et al. Promoting the
use of personal asthma action plans: a systematic
review. Prim Care Respir J. 2007;16(5):271–83.
34. Gibson PG, Powell H. Written action plans for
asthma: an evidence-based review of the key com-
ponents. Thorax. 2004;59(2):94–9.
35. Dennis SM, Zwar NA, Marks GB. Diagnosing asthma
in adults in primary care: a qualitative study of
Australian GPs’ experiences. Prim Care Respir J.
2010;19(1):52–6.
36. Kaplan A, Stanbrook M. Must family physicians use
spirometry in managing asthma patients?YES. Can
Fam Phys. 2010;56(2):126–8 (130, 132).
37. Merghani TH. Patterns of spirometry in asthmatic
patients presenting with respiratory symptoms. Int
J Med Sci Public Health. 2017;6(2):337–40.
Adv Ther
